Zealand Pharma
Market Cap
ø9.8b
Last Updated
2020/06/01 21:21 UTC
Data Sources
Company Financials +
Executive Summary
Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide based medicines in Denmark.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet with limited growth.
Similar Companies
Share Price & News
How has Zealand Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ZEAL's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-2.2%
ZEAL
2.0%
DK Biotechs
-0.7%
DK Market
1 Year Return
100.6%
ZEAL
36.1%
DK Biotechs
22.3%
DK Market
Return vs Industry: ZEAL exceeded the Danish Biotechs industry which returned 35.8% over the past year.
Return vs Market: ZEAL exceeded the Danish Market which returned 23% over the past year.
Shareholder returns
| ZEAL | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.2% | 2.0% | -0.7% |
| 30 Day | 14.2% | 6.9% | 7.0% |
| 90 Day | 2.1% | 12.5% | 4.3% |
| 1 Year | 100.6%100.6% | 37.2%36.1% | 24.7%22.3% |
| 3 Year | 118.0%118.0% | 28.6%25.9% | 40.5%28.8% |
| 5 Year | 121.7%121.7% | 66.6%61.3% | 51.6%32.5% |
Price Volatility Vs. Market
How volatile is Zealand Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Can We See Significant Institutional Ownership On The Zealand Pharma A/S (CPH:ZEAL) Share Register?2 months ago | Simply Wall St
Zealand Pharma A/S Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?2 months ago | Simply Wall St
Companies Like Zealand Pharma (CPH:ZEAL) Can Afford To Invest In GrowthValuation
Is Zealand Pharma undervalued compared to its fair value and its price relative to the market?
7.93x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ZEAL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ZEAL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ZEAL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: ZEAL is unprofitable, so we can't compare its PE Ratio to the Danish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ZEAL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ZEAL is overvalued based on its PB Ratio (7.9x) compared to the XE Biotechs industry average (4.3x).
Next Steps
Future Growth
How is Zealand Pharma forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
52.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ZEAL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ZEAL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ZEAL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ZEAL's revenue (55.2% per year) is forecast to grow faster than the Danish market (6.5% per year).
High Growth Revenue: ZEAL's revenue (55.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ZEAL is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Zealand Pharma performed over the past 5 years?
6.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ZEAL is currently unprofitable.
Growing Profit Margin: ZEAL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ZEAL is unprofitable, but has reduced losses over the past 5 years at a rate of 6% per year.
Accelerating Growth: Unable to compare ZEAL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZEAL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (17.1%).
Return on Equity
High ROE: ZEAL has a negative Return on Equity (-51.3%), as it is currently unprofitable.
Next Steps
Financial Health
How is Zealand Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: ZEAL's short term assets (DKK1.4B) exceed its short term liabilities (DKK187.7M).
Long Term Liabilities: ZEAL's short term assets (DKK1.4B) exceed its long term liabilities (DKK158.5M).
Debt to Equity History and Analysis
Debt Level: ZEAL is debt free.
Reducing Debt: ZEAL has no debt compared to 5 years ago when its debt to equity ratio was 148.2%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZEAL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ZEAL has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 14.6% each year.
Next Steps
Dividend
What is Zealand Pharma's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ZEAL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ZEAL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ZEAL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ZEAL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ZEAL's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.2yrs
Average management tenure
CEO
Emmanuel Dulac (50yo)
1.17yrs
Tenure
ø15,914,300
Compensation
Dr. Emmanuel Dulac, PharmD, PhD, MBA, has been Chief Executive Officer at Zealand Pharma A/S since April 22, 2019 and its President since 2019. He had been Chief Commercial Officer and Senior Vice Presiden ...
CEO Compensation Analysis
Compensation vs Market: Emmanuel's total compensation ($USD2.37M) is above average for companies of similar size in the Danish market ($USD1.64M).
Compensation vs Earnings: Insufficient data to compare Emmanuel's compensation with company performance.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & President | 1.17yrs | ø15.91m | no data | |
| Senior VP & CFO | 0.67yr | ø3.23m | no data | |
| Senior Project Director | 4.17yrs | ø400.00k | 0.026% DKK2.6m | |
| Executive VP of Research & Development and Chief Medical Officer | 1.17yrs | ø6.92m | 0.046% DKK4.5m | |
| Senior Vice President of Technical Development & Operations | 2.25yrs | no data | no data | |
| Interim Chief Scientific Officer & VP of Research | 0.83yr | no data | no data | |
| Investor Relations & Communications Officer | no data | no data | no data | |
| Head of Legal Affairs | 6.17yrs | no data | no data | |
| Head of Bioanalysis | no data | no data | no data | |
| Head of Molecular Pharmacology | no data | no data | no data |
1.2yrs
Average Tenure
47yo
Average Age
Experienced Management: ZEAL's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Senior Project Director | 4.17yrs | ø400.00k | 0.026% DKK2.6m | |
| Independent Director | 1.17yrs | ø367.00k | 0.011% DKK1.1m | |
| Co-Chair of the Clinical & Scientific Advisory Board & Director | 8.58yrs | ø450.00k | 0.014% DKK1.4m | |
| Independent Chairman of the Board | 5.17yrs | ø850.00k | 0.0027% DKK264.3k | |
| Member of Advisory Board | 8.58yrs | no data | no data | |
| Board Observer | no data | no data | no data | |
| Member of Advisory Board | 8.58yrs | no data | no data | |
| Member of Advisory Board | 8.58yrs | no data | no data | |
| Member of Advisory Board | 8.58yrs | no data | no data | |
| Independent Vice Chairman | 1.17yrs | ø467.00k | 0.0014% DKK131.7k |
8.6yrs
Average Tenure
64yo
Average Age
Experienced Board: ZEAL's board of directors are considered experienced (8.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.7%.
Top Shareholders
Company Information
Zealand Pharma A/S's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Zealand Pharma A/S
- Ticker: ZEAL
- Exchange: CPSE
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: ø9.753b
- Shares outstanding: 36.94m
- Website: https://www.zealandpharma.com
Number of Employees
Location
- Zealand Pharma A/S
- Sydmarken 11
- SOeborg
- Copenhagen
- Capital Region of Denmark
- 2860
- Denmark
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ZEAL | CPSE (OMX Nordic Exchange Copenhagen) | Yes | Ordinary Shares | DK | DKK | Nov 2010 |
| 0NZU | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | DKK | Nov 2010 |
| 22Z | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Nov 2010 |
| ZLDP.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Nov 2010 |
| ZEALC | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | DKK | Nov 2010 |
| ZEAL | NasdaqGS (Nasdaq Global Select) | ADR EACH REP 1 ORD SHS SPON | US | USD | Aug 2017 | |
| 22ZA | DB (Deutsche Boerse AG) | ADR EACH REP 1 ORD SHS SPON | DE | EUR | Aug 2017 |
Biography
Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide based medicines in Denmark. It has a portfolio of medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. Its product pipeline includes glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome; dasiglucagon, a stable glucagon analog for the treatment of severe hypoglycemia in diabetes and congenital hyperinsulinism, as well as for use in dual-hormone automated pump therapy for management of type 1 diabetes; and GLP-1/glucagon dual-acting agonist for obesity/diabetes. Zealand Pharma A/S has a collaboration agreement with Sanofi-Aventis Deutschland GmbH to market lixisenatide; and a license, research and development agreement with Alexion Pharmaceuticals, Inc. to develop novel therapies to treat complement mediated diseases, as well as a collaboration agreement with Boehringer Ingelheim International GmbH to advance novel GLP-1/glucagon dual-acting peptide receptor agonists. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/01 21:21 |
| End of Day Share Price | 2020/05/29 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.